Thomas F Gajewski Selected Research

Monatide (IMS 3015)

1/2018	WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia.
1/2013	A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas F Gajewski Research Topics

Disease

141	Neoplasms (Cancer) 05/2024 - 04/2002
68	Melanoma (Melanoma, Malignant) 01/2023 - 06/2003
14	Bites and Stings (Sting) 04/2024 - 11/2014
11	COVID-19 12/2022 - 01/2020
9	Neoplasm Metastasis (Metastasis) 01/2021 - 06/2003
7	Disease Progression 01/2018 - 02/2003
6	Renal Cell Carcinoma (Grawitz Tumor) 11/2016 - 04/2002
4	Experimental Melanoma 04/2024 - 05/2006
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2022 - 02/2003
3	Fever (Fevers) 01/2021 - 09/2017
3	Brain Neoplasms (Brain Tumor) 01/2019 - 12/2012
3	Urinary Bladder Neoplasms (Bladder Cancer) 01/2018 - 01/2016
3	Fatigue 09/2017 - 08/2014
2	Infections 01/2022 - 11/2021
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2020 - 01/2013
2	Exanthema (Rash) 01/2019 - 08/2014
2	Anemia 01/2018 - 02/2015
2	Ascites 01/2018 - 10/2006
2	Leukemia 01/2018 - 01/2006
2	Uveal melanoma 03/2017 - 06/2014
2	Hypersensitivity (Allergy) 01/2017 - 02/2010
2	Nausea 02/2015 - 08/2014
2	Myalgia 08/2014 - 02/2003
2	Inflammation (Inflammations) 04/2013 - 01/2012
1	Rheumatic Diseases (Rheumatism) 01/2023
1	Thrombosis (Thrombus) 12/2022
1	Aneuploidy (Aneuploid) 12/2022

Drug/Important Bio-Agent (IBA)

20	Neoplasm Antigens (Tumor Antigens)IBA 04/2024 - 12/2002
19	Immune Checkpoint InhibitorsIBA 05/2024 - 01/2016
19	AntigensIBA 01/2022 - 12/2002
13	Biomarkers (Surrogate Marker)IBA 12/2022 - 07/2010
13	CytokinesIBA 10/2022 - 05/2002
12	Proteins (Proteins, Gene)FDA Link 04/2024 - 02/2004
11	DNA (Deoxyribonucleic Acid)IBA 12/2022 - 11/2014
11	VaccinesIBA 01/2022 - 03/2004
10	IpilimumabIBA 01/2023 - 10/2010
8	pembrolizumabIBA 01/2023 - 01/2016
8	Peptides (Polypeptides)IBA 11/2019 - 06/2003
7	B7-H1 AntigenIBA 01/2023 - 04/2005
7	ChemokinesIBA 01/2021 - 10/2006
7	Interferon Type IIBA 01/2019 - 09/2011
7	Interleukin-2 (IL2)IBA 01/2014 - 05/2002
6	AntibodiesIBA 01/2022 - 06/2013
6	Monoclonal AntibodiesIBA 01/2021 - 07/2006
6	CateninsIBA 11/2019 - 01/2015
6	LigandsIBA 01/2019 - 01/2004
5	InterferonsIBA 01/2018 - 11/2014
4	VemurafenibIBA 01/2020 - 07/2012
4	NivolumabIBA 01/2020 - 01/2016
4	epacadostatIBA 01/2019 - 01/2017
4	cyclic guanosine monophosphate-adenosine monophosphateIBA 04/2016 - 11/2014
3	Tyrosine Kinase InhibitorsIBA 01/2023 - 06/2004
3	AutoantibodiesIBA 01/2023 - 11/2021
3	RNA (Ribonucleic Acid)IBA 10/2022 - 01/2016
3	SteroidsIBA 01/2022 - 06/2004
3	Transcription Factors (Transcription Factor)IBA 01/2020 - 01/2008
3	Imatinib Mesylate (Gleevec)FDA Link 05/2015 - 09/2013
2	vadimezanIBA 04/2024 - 05/2015
2	talimogene laherparepvecIBA 01/2023 - 09/2017
2	Angiotensin IIIBA 10/2022 - 11/2021
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 01/2020
2	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2021 - 07/2020
2	Nucleic AcidsIBA 01/2021 - 12/2020
2	Interleukin-6 (Interleukin 6)IBA 01/2021 - 07/2020
2	tocilizumab (atlizumab)FDA Link 01/2021 - 07/2020
2	C-Reactive ProteinIBA 01/2021 - 07/2020
2	cobimetinibIBA 01/2020 - 08/2014
2	Interleukin-12 (IL 12)IBA 11/2019 - 06/2003
2	Programmed Cell Death 1 ReceptorIBA 01/2019 - 11/2015
2	EnzymesIBA 11/2018 - 08/2014
2	Monatide (IMS 3015)IBA 01/2018 - 01/2013
2	Sirolimus (Rapamycin)FDA Link 01/2018 - 09/2012
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 03/2017 - 08/2014
2	AZD 6244IBA 03/2017 - 06/2014
2	Immunomodulating AgentsIBA 11/2016 - 04/2012
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 11/2016 - 02/2004
2	Interferon Regulatory Factor-3 (Interferon Regulatory Factor 3)IBA 04/2016 - 11/2014
2	Blocking AntibodiesIBA 01/2016 - 11/2015
2	Mitogen-Activated Protein KinasesIBA 11/2015 - 06/2014
2	Therapeutic UsesIBA 11/2015 - 05/2015
2	Temozolomide (Temodar)FDA LinkGeneric 06/2014 - 02/2004
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2013 - 02/2010
2	tipifarnib (R115777)IBA 12/2012 - 12/2004
2	EpitopesIBA 04/2012 - 01/2006
2	PerforinIBA 03/2012 - 10/2006
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2008 - 06/2004
2	superagonist SIYRIBA 05/2008 - 02/2004
2	MART-1 AntigenIBA 10/2006 - 06/2003
1	Toll-Like Receptor AgonistsIBA 04/2024
1	Peroxidase (Myeloperoxidase)IBA 12/2022
1	FibrinIBA 12/2022
1	Antiviral Agents (Antivirals)IBA 12/2022
1	fibrin fragment D (D-dimer)IBA 12/2022

Therapy/Procedure

72	Immunotherapy 05/2024 - 04/2005
62	Therapeutics 05/2024 - 06/2003
11	Drug Therapy (Chemotherapy) 01/2022 - 04/2002
5	Radiotherapy 12/2022 - 11/2014
3	Precision Medicine 01/2022 - 11/2016
3	Biological Therapy 09/2011 - 09/2007
2	Premedication 06/2004 - 02/2003